͵͵

News

Ebola virus hides out in brain

Monkeys treated with monoclonal antibodies fully recovered, but infection recurred
Kevin Zeng
By Kevin Zeng
April 16, 2022

The Ebola virus can hide in the brains of monkeys that have recovered after medical treatment without causing symptoms and lead to recurrent infections, according to a study by a that was published in the journal .

infectious disease threats known to humankind, with an . Ebola is known for a high level of , meaning the virus remains lurking in the body even after a patient has recovered. But where this hiding place is remains largely unknown.

This image shows Ebola virus particles (red) budding from the surface of kidney cell (blue).
National Institute of Allergy and Infectious Diseases/Flickr, CC BY-SA
This image shows Ebola virus particles (red) budding from the surface of kidney cell (blue).

In 2021, there were , all linked to previously infected survivors. Ebola also reemerged in that same year, linked to a survivor of the 2013-2016 Ebola outbreak.

Email Twitter19 Facebook902 LinkedIn Print  The Research Brief is a short take about interesting academic work. The big idea  The Ebola virus can hide in the brains of monkeys that have recovered after medical treatment without causing symptoms and lead to recurrent infections, according to a study by a team I led that was published in the journal Science Translational Medicine.  Ebola is one of the deadliest infectious disease threats known to humankind, with an average fatality rate of about 50%25. Ebola is known for a high level of viral persistence, meaning the virus remains lurking in the body even after a patient has recovered. But where this hiding place is remains largely unknown.  In 2021, there were three Ebola outbreaks in Africa, all linked to previously infected survivors. Ebola also reemerged in Guinea that same year, linked to a survivor of the 2013-2016 Ebola outbreak. Don’t let yourself be misled. Understand issues with help from experts A laboratory technician in full Personal protective equipment pipettes samples under a lab hood. The researchers conducted their study in a Biosafety Level 4 lab, the highest level of biocontainment required to safely study hazardous pathogens like Ebola.
John W. Braun, USAMRIID, CC BY-NC-ND
The researchers conducted their study in a Biosafety Level 4 lab, the highest level of biocontainment required to safely study hazardous pathogens like Ebola.

We wanted to better understand where the Ebola virus “hides” in the body of survivors and what triggers recurrent infections. So we examined 36 rhesus monkeys that had been treated for Ebola with , a type of treatment that helps the immune system mount an attack against an infection. These monkeys were deemed fully recovered with no symptoms of infection or detectable virus in their blood.

When we looked more closely at the tissues of different organs under a microscope, however, we found that about 20% of recovered monkeys still had visible Ebola virus located exclusively in the of the brain. This brain region produces, circulates and stores , which protects, supplies nutrients to and removes waste products from the brain.

Importantly, despite being asymptomatic at the start of our study, two of the monkeys we observed developed Ebola symptoms before dying at 30 and 39 days after their initial infection, respectively. Our findings suggest that the Ebola virus can hide dormant in the brains of survivors even after treatment, and the virus can reactivate and cause fatal infections later on.

This image shows the brain ventricular system of a rhesus monkey that survived Ebola virus infection, where brown indicates viral persistence.
Kevin Zeng, CC BY-NC-ND
This image shows the brain ventricular system of a rhesus monkey that survived Ebola virus infection, where brown indicates viral persistence.

Why it matters

Treatment with monoclonal antibodies is the current . But recurrent infections can occur even after apparently successful treatment, and patients can inadvertently transmit the virus and cause new outbreaks.

Our study underscores the importance of careful long-term medical follow-up of successfully treated Ebola survivors to counter the individual and public health cost of recurrent disease. This follow-up, however, will need to be conducted in a way that does not further .

What still isn’t known

We still don’t know why the Ebola virus persists in the brain and causes recurrent infections. It is also unclear whether this persistence might be related to monoclonal antibody treatments, and whether other types of therapies, such as antivirals, might produce a different effect. Researchers are still looking into what triggers relapses and whether there might be other parts of the body that may act as reservoirs.

What’s next

Our work highlights the need to more deeply investigate why the Ebola virus persists in the brain. Because the brain is to monoclonal antibodies, treatments may help prevent and clear persistent Ebola infection and related disease in the brain. Analyzing viral persistence at the may provide more insight.

This article is republished from under a Creative Commons license. Read the .

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition weekly.

Learn more
Kevin Zeng
Kevin Zeng

Kevin Zeng is a principal investigator at the U.S. Army Medical Research Institute of Infectious Diseases.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

Guiding grocery carts to shape healthy habits
Award

Guiding grocery carts to shape healthy habits

Nov. 21, 2024

Robert “Nate” Helsley will receive the Walter A. Shaw Young Investigator in Lipid Research Award at the 2025 ASBMB Annual Meeting, April 12–15 in Chicago.

Quantifying how proteins in microbe and host interact
Journal News

Quantifying how proteins in microbe and host interact

Nov. 20, 2024

“To develop better vaccines, we need new methods and a better understanding of the antibody responses that develop in immune individuals,” author Johan Malmström said.

Leading the charge for gender equity
Award

Leading the charge for gender equity

Nov. 19, 2024

Nicole Woitowich will receive the ASBMB Emerging Leadership Award at the 2025 ASBMB Annual meeting, April 12–15 in Chicago.

CRISPR gene editing: Moving closer to home
News

CRISPR gene editing: Moving closer to home

Nov. 17, 2024

With the first medical therapy approved, there’s a lot going on in the genome editing field, including the discovery of CRISPR-like DNA-snippers called Fanzors in an odd menagerie of eukaryotic critters.

Finding a missing piece for neurodegenerative disease research
News

Finding a missing piece for neurodegenerative disease research

Nov. 16, 2024

Ursula Jakob and a team at the University of Michigan have found that the molecule polyphosphate could be what scientists call the “mystery density” inside fibrils associated with Alzheimer’s, Parkinson’s and related conditions.

From the journals: JLR
Journal News

From the journals: JLR

Nov. 15, 2024

Enzymes as a therapeutic target for liver disease. Role of AMPK in chronic liver disease Zebrafish as a model for retinal dysfunction. Read about the recent JLR papers on these topics.